Biodesix (BDSX) Q1 2026 earnings review
Top-Line Acceleration Masks a Return to Cash Burn
Biodesix continues to execute phenomenally on the top line, with Q1 revenue accelerating to 42% YoY growth. Diagnostic test volumes surged 29%, and higher average revenue per test (ASP) fueled a beat that allowed management to raise FY26 guidance. However, the profitability narrative took a hit. After celebrating its first-ever positive Adjusted EBITDA in Q4 2025, the company reversed back to a $4.1M EBITDA loss in Q1. While management previously telegraphed Q1 seasonality, the sequential cash burn forced a heavy reliance on the ATM facility, raising $16.8M to keep the balance sheet afloat. The sales strategy is working, but shareholders are paying for it through dilution.
🐂 Bull Case
Total revenue grew 42% YoY, accelerating from the 20% growth seen in Q3 2025. The newly expanded primary care sales team is scaling rapidly and successfully driving test volume.
Gross margin printed at 84% (82% excluding a one-time tax recovery), reflecting a stable, highly profitable unit economics model as test workflows optimize.
🐻 Bear Case
Adjusted EBITDA reversed from positive $0.5M in Q4 back to negative $4.1M. Seasonal headwinds (deductible resets) are real, but the company remains dependent on operational leverage that hasn't fully arrived.
Cash balance looks healthy at $25.6M, but only because the company tapped its ATM facility for $16.8M in the quarter, diluting shareholders to fund current operations.
⚖️ Verdict: ⚪
Neutral. The commercial execution is pristine, and the raised guidance proves the primary care strategy is working. However, the heavy ATM usage and return to a sequential EBITDA loss mean the company is still paying a steep price for this growth.
Key Themes
Diagnostic Volume and ASP Expansion
The core diagnostics business is accelerating aggressively. Revenue reached $22.3M (+37% YoY) driven by a 29% increase in test volumes (17,800 tests). Crucially, average revenue per test is rising, validating management's efforts to secure broader payer coverage and streamline revenue cycle management. The strategic pivot to target primary care physicians is officially paying dividends.
Development Services Breakout
Development Services revenue surged 99% YoY to $3.3M, an accelerating trend from prior quarters. This segment—fueled by biopharma partnerships—is transforming from a side project into a meaningful, high-margin revenue contributor that validates Biodesix's underlying R&D platform.
Heavy Reliance on ATM Dilution
The company ended the quarter with $25.6M in cash, a 35% increase from Q4 2025. However, this optical improvement masks an underlying operational cash burn, as the increase was entirely funded by $16.8M in at-the-market (ATM) equity sales. The gap between GAAP net losses (-$7.8M) and cash generation remains a vital concern for current equity holders.
SG&A Bloat Weighs on Operating Leverage
Operating expenses grew 18% YoY to $27.6M. While management notes this is to support the expanded sales team, the 19% increase in sales, marketing, and general administrative costs means the company is still spending heavily to acquire its growth. Investors must monitor whether these new reps can mature enough to scale revenue without requiring linear headcount additions.
Other KPIs
Accelerating significantly from 79.4% a year ago. Even excluding a $0.4M one-time sales tax recovery, the base gross margin of 82% represents a 300-basis-point YoY improvement. This showcases excellent laboratory optimization and the benefit of a higher ASP.
A 30% improvement compared to the -$11.1M recorded in Q1 2025, but still a steep drop from the near-breakeven profile teased in Q4 2025. The bottom line must demonstrate sequential improvement in Q2 to maintain investor confidence in the path to profitability.
Guidance
Accelerating. The company raised its prior guidance range ($106-$112M). The new midpoint implies 25% YoY growth versus FY25, showcasing immense confidence in the primary care sales pipeline and Development Services backlog.
Stable. The company is guiding to maintain its elite gross margin profile, giving them the fundamental unit economics needed to eventually reach GAAP profitability.
Key Questions
ATM Strategy and Dilution Floor
With $16.8M raised via the ATM facility in Q1 despite previous assurances of a 'de-risked' balance sheet in Q4, what is the internal cash threshold required before tapping equity markets, and should investors expect continuous dilution through 2026?
Sequential Margin Recovery
Q1 experienced a sequential step-down in Adjusted EBITDA, attributed in part to seasonal deductible resets. What is the precise sequential trajectory expected for Q2 and Q3 to prove Q4 2025's profitability wasn't a one-off anomaly?
Sales Rep Maturation Metrics
SG&A grew 19% to support the expanded sales team. What is the current average time-to-productivity for the newly deployed primary care reps compared to your legacy pulmonology reps?